InVasc Therapeutics, Inc.

InVasc Therapeutics was a clinical-stage biopharmaceutical company focused on developing small molecule drugs and combination therapies targeting metabolic and cardiovascular diseases such as diabetes complications, hypertension, nephropathy, atherosclerosis, and myocardial infarction. Its most advanced asset was INV‑144—a combination therapy evaluated in a completed Phase II trial versus losartan potassium in patients with hypertension and type II diabetes with nephropathy. The company also explored novel antihypertensive agents derived from alpha-lipoic acid. As of early/mid‑2025 there are no signs of ongoing operations or new pipeline progress.